Jim Cramer on Chemours: "I Think it's Chronically Undervalued"

The Chemours Company (NYSE:CC) is one of the stocks Jim Cramer shared his opinions on. A caller asked for guidance on the stock, and Cramer replied:

“You know, I think it’s chronically undervalued, but I have to tell you, because people continue to think that it’s got problems with forever chemicals, I don’t think it does. I think they put them behind it, but I’m not going to touch it because the plaintiffs’… that powerful.”

The Chemours Company (NYSE:CC) delivers specialty chemicals across industries. The company’s portfolio includes refrigerants, pigments, resins, coatings, and advanced materials used in coatings, electronics, packaging, energy, transportation, and medical applications. On September 23, Mizuho analyst John Roberts increased Chemours’ price target to $19 from $16 while maintaining an Outperform rating. The analyst noted that per- and polyfluoroalkyl substance settlement progress is favorable and that stronger market valuations support the higher target.

While we acknowledge the potential of CC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.